CL2018002340A1 - Anticuerpos para il-17c - Google Patents

Anticuerpos para il-17c

Info

Publication number
CL2018002340A1
CL2018002340A1 CL2018002340A CL2018002340A CL2018002340A1 CL 2018002340 A1 CL2018002340 A1 CL 2018002340A1 CL 2018002340 A CL2018002340 A CL 2018002340A CL 2018002340 A CL2018002340 A CL 2018002340A CL 2018002340 A1 CL2018002340 A1 CL 2018002340A1
Authority
CL
Chile
Prior art keywords
antibodies
antibody fragments
human
psoriasis
refers
Prior art date
Application number
CL2018002340A
Other languages
English (en)
Inventor
Jan Dominik Haas
Jürgen Klattig
Nick Ernest René Vandeghinste
Original Assignee
Galapagos Nv
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Morphosys Ag filed Critical Galapagos Nv
Publication of CL2018002340A1 publication Critical patent/CL2018002340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS O FRAGMENTOS DE ANTICUERPO QUE SE UNEN A  IL-17C HUMANA. EN PARTICULAR, SE REFIERE A ANTICUERPOS O FRAGMENTOS DE ANTICUERPO QUE TIENEN PROPIEDADES BENEFICIOSAS COMBINADAS Y POR LO TANTO, SON ÚTILES PARA EL TRATAMIENTO DE SERES HUMANOS QUE TIENEN, POR EJEMPLO, DERMATITIS ATÓPICA O PSORIASIS.
CL2018002340A 2016-02-19 2018-08-16 Anticuerpos para il-17c CL2018002340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16156582 2016-02-19
EP16156651 2016-02-22

Publications (1)

Publication Number Publication Date
CL2018002340A1 true CL2018002340A1 (es) 2018-11-23

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002340A CL2018002340A1 (es) 2016-02-19 2018-08-16 Anticuerpos para il-17c

Country Status (33)

Country Link
US (5) US20190048071A1 (es)
EP (1) EP3416983B1 (es)
JP (2) JP6535139B2 (es)
KR (1) KR102715157B1 (es)
CN (1) CN108699143B (es)
AU (1) AU2017219837B2 (es)
BR (1) BR112018016798A2 (es)
CA (1) CA3014842A1 (es)
CL (1) CL2018002340A1 (es)
CO (1) CO2018008724A2 (es)
CU (1) CU20180087A7 (es)
CY (1) CY1124296T1 (es)
DK (1) DK3416983T3 (es)
EA (1) EA037813B1 (es)
EC (1) ECSP18070641A (es)
ES (1) ES2877376T3 (es)
HR (1) HRP20211059T1 (es)
HU (1) HUE054755T2 (es)
IL (1) IL260733B2 (es)
LT (1) LT3416983T (es)
MA (2) MA44227B1 (es)
MD (1) MD3416983T2 (es)
MX (1) MX2018009860A (es)
PH (1) PH12018501739A1 (es)
PL (1) PL3416983T3 (es)
RS (1) RS62012B1 (es)
SG (1) SG11201806161TA (es)
SI (1) SI3416983T1 (es)
SM (1) SMT202100361T1 (es)
TN (1) TN2018000289A1 (es)
TW (1) TW201734041A (es)
WO (1) WO2017140831A1 (es)
ZA (1) ZA201806249B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604566B2 (en) * 2015-10-05 2020-03-31 Galapagos Nv Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
HRP20211059T1 (hr) * 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c
TW201919698A (zh) * 2017-09-25 2019-06-01 德商莫菲西斯公司 異位性皮炎之治療
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography
EP4061825A1 (en) * 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2005295421A1 (en) 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
US20070129302A1 (en) * 2005-10-18 2007-06-07 Zeren Gao Il-17c antagonists and methods of using the same
EP2064237A2 (en) 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
ME03073B (me) * 2011-10-19 2019-01-20 Galapagos Nv Ant agonisti il17с za lečenje zapaljenskih poremećaja
JP2015521591A (ja) * 2012-06-12 2015-07-30 オレガ・バイオテック Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用
EP3233915B1 (en) * 2014-12-15 2024-08-28 MorphoSys AG Antibodies for il-17c
HRP20211059T1 (hr) 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c

Also Published As

Publication number Publication date
KR20180109977A (ko) 2018-10-08
JP2019511910A (ja) 2019-05-09
RS62012B1 (sr) 2021-07-30
CN108699143B (zh) 2021-11-09
MX2018009860A (es) 2019-03-28
WO2017140831A1 (en) 2017-08-24
LT3416983T (lt) 2021-07-12
ECSP18070641A (es) 2018-10-31
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
US20190202906A1 (en) 2019-07-04
MA44227B1 (fr) 2021-06-30
IL260733B2 (en) 2024-03-01
US10633439B2 (en) 2020-04-28
US10259869B2 (en) 2019-04-16
MA44227A (fr) 2018-12-26
SMT202100361T1 (it) 2021-07-12
EA201891594A1 (ru) 2019-01-31
EP3416983B1 (en) 2021-04-07
US20250074978A1 (en) 2025-03-06
EP3416983A1 (en) 2018-12-26
JP6535139B2 (ja) 2019-06-26
IL260733B1 (en) 2023-11-01
DK3416983T3 (en) 2021-06-21
MD3416983T2 (ro) 2021-08-31
CY1124296T1 (el) 2022-11-25
TN2018000289A1 (en) 2020-01-16
PL3416983T3 (pl) 2021-10-25
SG11201806161TA (en) 2018-08-30
KR102715157B1 (ko) 2024-10-10
JP2019162119A (ja) 2019-09-26
CO2018008724A2 (es) 2018-08-31
ES2877376T3 (es) 2021-11-16
AU2017219837B2 (en) 2023-08-17
US11987621B2 (en) 2024-05-21
BR112018016798A2 (en) 2018-12-26
IL260733A (es) 2018-09-20
HUE054755T2 (hu) 2021-09-28
PH12018501739A1 (en) 2019-06-10
MA43088B1 (fr) 2020-10-28
ZA201806249B (en) 2020-02-26
MA43088A1 (fr) 2019-05-31
SI3416983T1 (sl) 2021-08-31
HRP20211059T1 (hr) 2021-10-01
JP6916834B2 (ja) 2021-08-11
EA037813B1 (ru) 2021-05-24
US20190048071A1 (en) 2019-02-14
CA3014842A1 (en) 2017-08-24
TW201734041A (zh) 2017-10-01
US20180340024A1 (en) 2018-11-29
US20200216529A1 (en) 2020-07-09
AU2017219837A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
CL2018002340A1 (es) Anticuerpos para il-17c
CO2019003047A2 (es) Anticuerpos anti-il-33 y usos de los mismos
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
EA202091540A1 (ru) Антитела к lilrb2
CL2017003024A1 (es) Tratamiento para el cancer a traves de la manipulación de microflora comensal
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
CO2017010618A2 (es) Anticuerpos contra icos
MX370807B (es) Anticuerpos que se unen a axl.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
AR119639A1 (es) Moléculas de anticuerpo para cd73 y sus usos